Name (Synonyms) | Correlation | |
---|---|---|
drug1848 | Placebo of excipient(s) will be administered Wiki | 1.00 |
drug1000 | Glucose tablets Wiki | 1.00 |
drug267 | Azithromycin 500Mg Oral Tablet Wiki | 1.00 |
drug1098 | Hydroxychloroquine 200 Mg Oral Tablet Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D013577 | Syndrome NIH | 0.11 |
D055371 | Acute Lung Injury NIH | 0.10 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.10 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.09 |
D003141 | Communicable Diseases NIH | 0.09 |
D007239 | Infection NIH | 0.06 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The aim of the study is to clinically use bovine Lf as a safe antiviral adjuvant for treatment and to assess the potential in reducing mortality and morbidity rates in COVID-19 patients. The study was approved by the ethical committee of the Egyptian Center for Research and Regenerative Medicine in 11-5-2020.
Description: Comparing the influence of the intervention on the Survival rate.
Measure: Survival rate. Time: up to 8 weeks.Description: For mild/moderate symptoms patients: fever, cough and other symptoms relieved with improved lung CT - For severe symptoms patients: fever, cough and other symptoms relieved with improved lung CT, and oxygen saturation by pulse oximetry (SPO2 )> 93% for nonasthmatic patients, and from 88-92% in asthmatic patients.
Measure: Rate of disease remission. Time: up to 4 weeks.Description: Comparing the influence of the intervention on the PCR negative results.
Measure: The number of patients with PCR negative results. Time: up to 4 weeks.Description: Recording the changes from severe to moderate or mild and the time taken.
Measure: Mean change in the disease severity (clinical assessment). Time: up to 4 weeks.Description: Recording the changes in blood pressure mmHg.
Measure: Mean change in blood pressure. Time: up to 4 weeks.Description: Recording the changes in heart rate in beat/second.
Measure: Mean change in heart beats. Time: up to 4 weeks.Description: Recording the changes in body temperature in Celsius.
Measure: Mean change in body temperature. Time: up to 4 weeks.Description: Recording the changes in the respiratory rate in breath/minute.
Measure: Mean change in body respiratory rate. Time: up to 4 weeks.Description: Recording the changes in arterial oxygen saturation in mmHg.
Measure: Mean change in oxygen saturation. Time: up to 4 weeks.Description: Recording the changes in the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PF ratio).
Measure: Mean change in the ratio in arterial oxygen partial pressure to fractional inspired oxygen (PF ratio). Time: up to 4 weeks.Description: Recording the changes in complete blood picture (CBC) in cells per liter.
Measure: Mean change in complete blood picture (CBC). Time: up to 4 weeks.Description: Recording the changes in C reactive protein (CRP) in mg/L.
Measure: Mean change in C reactive protein (CRP). Time: up to 4 weeks.Description: Recording the changes in erythrocyte sedimentation rate (ESR) in mm/hr.
Measure: Mean change in erythrocyte sedimentation rate (ESR). Time: up to 4 weeks.Description: Recording the changes in D-dimer in ng/mL.
Measure: Mean change in D-dimer. Time: up to 4 weeks.Description: Recording the changes in ferritin in ng/mL.
Measure: Mean change in ferritin. Time: up to 4 weeks.Description: Recording the changes in liver Albumin in g/L.
Measure: Mean change in liver Albumin. Time: up to 4 weeks.Description: Recording the changes in total and direct Bilirubin in mg/dL.
Measure: Mean change in total and direct Bilirubin. Time: up to 4 weeks.Description: Recording the changes in prothrombin time (PT), partial thromboplastin time (PTT ) in seconds and calculating International Normalized Ratio (INR).
Measure: Mean change in prothrombin time (PT) and partial thromboplastin time (PTT ). Time: up to 4 weeks.Description: Recording the changes in aspartate aminotransferase (AST) in IU/L.
Measure: Mean change in aspartate aminotransferase (AST). Time: up to 4 weeks.Description: Recording the changes in Alanine Aminotransferase (ALT) in IU/L.
Measure: Mean change in Alanine Aminotransferase (ALT). Time: up to 4 weeks.Description: Recording the changes in Blood Urea Nitrogen (BUN) in mg/dL.
Measure: Mean change in Blood Urea Nitrogen (BUN). Time: up to 4 weeks.Description: Recording the changes in Serum Creatinine in mg/dL.
Measure: Mean change in Serum Creatinine. Time: up to 4 weeks.Description: Recording the changes in Serum Creatinine in ml/min.
Measure: Mean change in Serum Creatinine clearance. Time: up to 4 weeks.Description: Recording the changes in Glomerular filtration rate (GFR ) ml/min/m2.
Measure: Mean change in Glomerular filtration rate (GFR ). Time: up to 4 weeks.Description: Recording the changes in interleukin-1 (IL-1) in pg/ml.
Measure: The mean change in serum interleukin-1 (IL-1). Time: up to 4 weeks.Description: Recording the changes in interleukin-6 (IL-6) in pg/ml.
Measure: The mean change in serum interleukin-6 (IL-6). Time: up to 4 weeks.Description: Recording the changes in interleukin-10 (IL-10) in pg/ml.
Measure: The mean change in serum interleukin-10 (IL-10). Time: up to 4 weeks.Description: Recording the changes in tumor necrosis factor-alpha (TNF alpha) in ng/ml.
Measure: The mean change in serum tumor necrosis factor-alpha (TNF alpha). Time: up to 4 weeks.Description: Recording the changes in immunoglobulin G (IgG) in ng/ml.
Measure: Mean changes in immunoglobulin G (IgG). Time: up to 4 weeks.Description: Recording the changes in immunoglobulin M (IgM) in ng/ml.
Measure: Mean changes in immunoglobulin M (IgM). Time: up to 4 weeks.Description: Recording the changes in PCR viral load in copies/mL.
Measure: The mean change in PCR viral load. Time: up to 4 weeks.Description: Recording the changes in lung CT.
Measure: Mean change in lung CT manifestation. Time: up to 4 weeks.Description: Recording any unexpected Adverse Events of the intervention.
Measure: Nature and severity of Adverse Events. Time: up to 4 weeks.Description: Recording the changes (the average time of lung imaging recovery), as assessed by lung CT.
Measure: Time for lung recovery. Time: up to 8 weeks.Description: Recording the changes the event of missed drug doses.
Measure: The number of missed drug doses among each treatment group. Time: up to 4 weeks.